ENTRY       hsa05231                    Pathway
NAME        Choline metabolism in cancer - Homo sapiens (human)
DESCRIPTION Abnormal choline metabolism is emerging as a metabolic hallmark that is associated with oncogenesis and tumour progression. Following transformation, oncogenic signalling via pathways such as the RAS and PI3K-AKT pathways, and transcription factors associated with oncogenesis such as hypoxia-inducible factor 1 (HIF1) mediate overexpression and activation of choline cycle enzymes, which causes increased levels of choline-containing precursors and breakdown products of membrane phospholipids. These products of choline phospholipid metabolism, such as phosphocholine (PCho), diacylglycerol (DAG) and phosphatidic acid, may function as second messengers that are essential for the mitogenic activity of growth factors, particularly in the activation of the ras-raf-1-MAPK cascade and protein kinase C pathway.
CLASS       Human Diseases; Cancer: overview
PATHWAY_MAP hsa05231  Choline metabolism in cancer
ORGANISM    Homo sapiens (human) [GN:hsa]
GENE        10000  AKT3; AKT serine/threonine kinase 3 [KO:K04456] [EC:2.7.11.1]
            100137049  PLA2G4B; phospholipase A2 group IVB [KO:K16342] [EC:3.1.1.4]
            10163  WASF2; WASP family member 2 [KO:K05748]
            10434  LYPLA1; lysophospholipase 1 [KO:K06128] [EC:3.1.1.5]
            10810  WASF3; WASP family member 3 [KO:K06083]
            110117499  P3R3URF-PIK3R3; P3R3URF-PIK3R3 readthrough [KO:K02649]
            1119  CHKA; choline kinase alpha [KO:K14156] [EC:2.7.1.32 2.7.1.82]
            1120  CHKB; choline kinase beta [KO:K14156] [EC:2.7.1.32 2.7.1.82]
            123745  PLA2G4E; phospholipase A2 group IVE [KO:K16342] [EC:3.1.1.4]
            126969  SLC44A3; solute carrier family 44 member 3 [KO:K15282]
            139189  DGKK; diacylglycerol kinase kappa [KO:K00901] [EC:2.7.1.107]
            1606  DGKA; diacylglycerol kinase alpha [KO:K00901] [EC:2.7.1.107]
            1607  DGKB; diacylglycerol kinase beta [KO:K00901] [EC:2.7.1.107]
            1608  DGKG; diacylglycerol kinase gamma [KO:K00901] [EC:2.7.1.107]
            160851  DGKH; diacylglycerol kinase eta [KO:K00901] [EC:2.7.1.107]
            1609  DGKQ; diacylglycerol kinase theta [KO:K00901] [EC:2.7.1.107]
            1950  EGF; epidermal growth factor [KO:K04357]
            1956  EGFR; epidermal growth factor receptor [KO:K04361] [EC:2.7.10.1]
            1978  EIF4EBP1; eukaryotic translation initiation factor 4E binding protein 1 [KO:K07205]
            204962  SLC44A5; solute carrier family 44 member 5 [KO:K15377]
            207  AKT1; AKT serine/threonine kinase 1 [KO:K04456] [EC:2.7.11.1]
            208  AKT2; AKT serine/threonine kinase 2 [KO:K04456] [EC:2.7.11.1]
            23396  PIP5K1C; phosphatidylinositol-4-phosphate 5-kinase type 1 gamma [KO:K00889] [EC:2.7.1.68]
            23446  SLC44A1; solute carrier family 44 member 1 [KO:K06515]
            2353  FOS; Fos proto-oncogene, AP-1 transcription factor subunit [KO:K04379]
            2475  MTOR; mechanistic target of rapamycin kinase [KO:K07203] [EC:2.7.11.1]
            255189  PLA2G4F; phospholipase A2 group IVF [KO:K16342] [EC:3.1.1.4]
            283748  PLA2G4D; phospholipase A2 group IVD [KO:K16342] [EC:3.1.1.4]
            2885  GRB2; growth factor receptor bound protein 2 [KO:K04364]
            3091  HIF1A; hypoxia inducible factor 1 subunit alpha [KO:K08268]
            3265  HRAS; HRas proto-oncogene, GTPase [KO:K02833]
            3725  JUN; Jun proto-oncogene, AP-1 transcription factor subunit [KO:K04448]
            3845  KRAS; KRAS proto-oncogene, GTPase [KO:K07827]
            4893  NRAS; NRAS proto-oncogene, GTPase [KO:K07828]
            5130  PCYT1A; phosphate cytidylyltransferase 1A, choline [KO:K00968] [EC:2.7.7.15]
            5154  PDGFA; platelet derived growth factor subunit A [KO:K04359]
            5155  PDGFB; platelet derived growth factor subunit B [KO:K17386]
            5156  PDGFRA; platelet derived growth factor receptor alpha [KO:K04363] [EC:2.7.10.1]
            5159  PDGFRB; platelet derived growth factor receptor beta [KO:K05089] [EC:2.7.10.1]
            5170  PDPK1; 3-phosphoinositide dependent protein kinase 1 [KO:K06276] [EC:2.7.11.1]
            5290  PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha [KO:K00922] [EC:2.7.1.153]
            5291  PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta [KO:K00922] [EC:2.7.1.153]
            5293  PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta [KO:K00922] [EC:2.7.1.153]
            5295  PIK3R1; phosphoinositide-3-kinase regulatory subunit 1 [KO:K02649]
            5296  PIK3R2; phosphoinositide-3-kinase regulatory subunit 2 [KO:K02649]
            5321  PLA2G4A; phospholipase A2 group IVA [KO:K16342] [EC:3.1.1.4]
            5335  PLCG1; phospholipase C gamma 1 [KO:K01116] [EC:3.1.4.11]
            5337  PLD1; phospholipase D1 [KO:K01115] [EC:3.1.4.4]
            5338  PLD2; phospholipase D2 [KO:K01115] [EC:3.1.4.4]
            5578  PRKCA; protein kinase C alpha [KO:K02677] [EC:2.7.11.13]
            5579  PRKCB; protein kinase C beta [KO:K19662] [EC:2.7.11.13]
            5582  PRKCG; protein kinase C gamma [KO:K19663] [EC:2.7.11.13]
            5594  MAPK1; mitogen-activated protein kinase 1 [KO:K04371] [EC:2.7.11.24]
            5595  MAPK3; mitogen-activated protein kinase 3 [KO:K04371] [EC:2.7.11.24]
            5599  MAPK8; mitogen-activated protein kinase 8 [KO:K04440] [EC:2.7.11.24]
            5601  MAPK9; mitogen-activated protein kinase 9 [KO:K04440] [EC:2.7.11.24]
            5602  MAPK10; mitogen-activated protein kinase 10 [KO:K04440] [EC:2.7.11.24]
            56034  PDGFC; platelet derived growth factor C [KO:K05450]
            5604  MAP2K1; mitogen-activated protein kinase kinase 1 [KO:K04368] [EC:2.7.12.2]
            5605  MAP2K2; mitogen-activated protein kinase kinase 2 [KO:K04369] [EC:2.7.12.2]
            56261  GPCPD1; glycerophosphocholine phosphodiesterase 1 [KO:K18695] [EC:3.1.4.2]
            56994  CHPT1; choline phosphotransferase 1 [KO:K00994] [EC:2.7.8.2]
            57153  SLC44A2; solute carrier family 44 member 2 (CTL2 blood group) [KO:K15377]
            5879  RAC1; Rac family small GTPase 1 [KO:K04392]
            5880  RAC2; Rac family small GTPase 2 [KO:K07860]
            5881  RAC3; Rac family small GTPase 3 [KO:K07861]
            5894  RAF1; Raf-1 proto-oncogene, serine/threonine kinase [KO:K04366] [EC:2.7.11.1]
            5900  RALGDS; ral guanine nucleotide dissociation stimulator [KO:K08732]
            6009  RHEB; Ras homolog, mTORC1 binding [KO:K07208]
            60482  SLC5A7; solute carrier family 5 member 7 [KO:K14387]
            6198  RPS6KB1; ribosomal protein S6 kinase B1 [KO:K04688] [EC:2.7.11.1]
            6199  RPS6KB2; ribosomal protein S6 kinase B2 [KO:K04688] [EC:2.7.11.1]
            6580  SLC22A1; solute carrier family 22 member 1 [KO:K08198]
            6581  SLC22A3; solute carrier family 22 member 3 [KO:K08200]
            6582  SLC22A2; solute carrier family 22 member 2 [KO:K08199]
            6583  SLC22A4; solute carrier family 22 member 4 [KO:K08202]
            6584  SLC22A5; solute carrier family 22 member 5 [KO:K08202]
            6654  SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 [KO:K03099]
            6655  SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 [KO:K03099]
            6667  SP1; Sp1 transcription factor [KO:K04684]
            7248  TSC1; TSC complex subunit 1 [KO:K07206]
            7249  TSC2; TSC complex subunit 2 [KO:K07207]
            7454  WAS; WASP actin nucleation promoting factor [KO:K05747]
            80310  PDGFD; platelet derived growth factor D [KO:K05450]
            80736  SLC44A4; solute carrier family 44 member 4 [KO:K15377]
            8394  PIP5K1A; phosphatidylinositol-4-phosphate 5-kinase type 1 alpha [KO:K00889] [EC:2.7.1.68]
            8395  PIP5K1B; phosphatidylinositol-4-phosphate 5-kinase type 1 beta [KO:K00889] [EC:2.7.1.68]
            8503  PIK3R3; phosphoinositide-3-kinase regulatory subunit 3 [KO:K02649]
            8525  DGKZ; diacylglycerol kinase zeta [KO:K00901] [EC:2.7.1.107]
            8526  DGKE; diacylglycerol kinase epsilon [KO:K00901] [EC:2.7.1.107]
            8527  DGKD; diacylglycerol kinase delta [KO:K00901] [EC:2.7.1.107]
            8605  PLA2G4C; phospholipase A2 group IVC [KO:K16342] [EC:3.1.1.4]
            8611  PLPP1; phospholipid phosphatase 1 [KO:K01080] [EC:3.1.3.4]
            8612  PLPP2; phospholipid phosphatase 2 [KO:K01080] [EC:3.1.3.4]
            8613  PLPP3; phospholipid phosphatase 3 [KO:K01080] [EC:3.1.3.4]
            8681  JMJD7-PLA2G4B; JMJD7-PLA2G4B readthrough [KO:K16342] [EC:3.1.1.4]
            8936  WASF1; WASP family member 1 [KO:K05753]
            9162  DGKI; diacylglycerol kinase iota [KO:K00901] [EC:2.7.1.107]
            9468  PCYT1B; phosphate cytidylyltransferase 1B, choline [KO:K00968] [EC:2.7.7.15]
COMPOUND    C00093  sn-Glycerol 3-phosphate
            C00114  Choline
            C00157  Phosphatidylcholine
            C00162  Fatty acid
            C00165  Diacylglycerol
            C00307  CDP-choline
            C00416  Phosphatidate
            C00588  Choline phosphate
            C00670  sn-Glycero-3-phosphocholine
            C04230  1-Acyl-sn-glycero-3-phosphocholine
            C05981  Phosphatidylinositol-3,4,5-trisphosphate
REFERENCE   PMID:22089420
  AUTHORS   Glunde K, Bhujwalla ZM, Ronen SM
  TITLE     Choline metabolism in malignant transformation.
  JOURNAL   Nat Rev Cancer 11:835-48 (2011)
            DOI:10.1038/nrc3162
REFERENCE   PMID:19935796
  AUTHORS   Beloueche-Babari M, Chung YL, Al-Saffar NM, Falck-Miniotis M, Leach MO
  TITLE     Metabolic assessment of the action of targeted cancer therapeutics using magnetic resonance spectroscopy.
  JOURNAL   Br J Cancer 102:1-7 (2010)
            DOI:10.1038/sj.bjc.6605457
REFERENCE   PMID:22429397
  AUTHORS   Abalsamo L, Spadaro F, Bozzuto G, Paris L, Cecchetti S, Lugini L, Iorio E, Molinari A, Ramoni C, Podo F
  TITLE     Inhibition of phosphatidylcholine-specific phospholipase C results in loss of mesenchymal traits in metastatic breast cancer cells.
  JOURNAL   Breast Cancer Res 14:R50 (2012)
            DOI:10.1186/bcr3151
REFERENCE   PMID:19264150
  AUTHORS   Foster DA
  TITLE     Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells.
  JOURNAL   Biochim Biophys Acta 1791:949-55 (2009)
            DOI:10.1016/j.bbalip.2009.02.009
REFERENCE   PMID:16432178
  AUTHORS   Beloueche-Babari M, Jackson LE, Al-Saffar NM, Eccles SA, Raynaud FI, Workman P, Leach MO, Ronen SM
  TITLE     Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells.
  JOURNAL   Mol Cancer Ther 5:187-96 (2006)
            DOI:10.1158/1535-7163.MCT-03-0220
REFERENCE   PMID:23350810
  AUTHORS   Ridgway ND
  TITLE     The role of phosphatidylcholine and choline metabolites to cell proliferation and survival.
  JOURNAL   Crit Rev Biochem Mol Biol 48:20-38 (2013)
            DOI:10.3109/10409238.2012.735643
REFERENCE   PMID:22921309
  AUTHORS   Awwad HM, Geisel J, Obeid R
  TITLE     The role of choline in prostate cancer.
  JOURNAL   Clin Biochem 45:1548-53 (2012)
            DOI:10.1016/j.clinbiochem.2012.08.012
REFERENCE   PMID:16230400
  AUTHORS   Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, D'Ascenzo S, Millimaggi D, Pavan A, Dolo V, Canevari S, Podo F
  TITLE     Alterations of choline phospholipid metabolism in ovarian tumor progression.
  JOURNAL   Cancer Res 65:9369-76 (2005)
            DOI:10.1158/0008-5472.CAN-05-1146
REFERENCE   PMID:14523987
  AUTHORS   Ackerstaff E, Glunde K, Bhujwalla ZM
  TITLE     Choline phospholipid metabolism: a target in cancer cells?
  JOURNAL   J Cell Biochem 90:525-33 (2003)
            DOI:10.1002/jcb.10659
REFERENCE   PMID:23076158
  AUTHORS   Park JB, Lee CS, Jang JH, Ghim J, Kim YJ, You S, Hwang D, Suh PG, Ryu SH
  TITLE     Phospholipase signalling networks in cancer.
  JOURNAL   Nat Rev Cancer 12:782-92 (2012)
            DOI:10.1038/nrc3379
REFERENCE   PMID:19855431
  AUTHORS   Yalcin A, Clem B, Makoni S, Clem A, Nelson K, Thornburg J, Siow D, Lane AN, Brock SE, Goswami U, Eaton JW, Telang S, Chesney J
  TITLE     Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling.
  JOURNAL   Oncogene 29:139-49 (2010)
            DOI:10.1038/onc.2009.317
REFERENCE   PMID:21793073
  AUTHORS   Glunde K, Jiang L, Moestue SA, Gribbestad IS
  TITLE     MRS and MRSI guidance in molecular medicine: targeting and monitoring of choline and glucose metabolism in cancer.
  JOURNAL   NMR Biomed 24:673-90 (2011)
            DOI:10.1002/nbm.1751
REFERENCE   PMID:19136975
  AUTHORS   Scott SA, Selvy PE, Buck JR, Cho HP, Criswell TL, Thomas AL, Armstrong MD, Arteaga CL, Lindsley CW, Brown HA
  TITLE     Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
  JOURNAL   Nat Chem Biol 5:108-17 (2009)
            DOI:10.1038/nchembio.140
REFERENCE   PMID:14517341
  AUTHORS   Foster DA, Xu L
  TITLE     Phospholipase D in cell proliferation and cancer.
  JOURNAL   Mol Cancer Res 1:789-800 (2003)
REFERENCE   PMID:20528734
  AUTHORS   Zhou H, Huang S
  TITLE     mTOR signaling in cancer cell motility and tumor metastasis.
  JOURNAL   Crit Rev Eukaryot Gene Expr 20:1-16 (2010)
            DOI:10.1615/critreveukargeneexpr.v20.i1.10
REL_PATHWAY hsa00564  Glycerophospholipid metabolism
            hsa04010  MAPK signaling pathway
            hsa04150  mTOR signaling pathway
            hsa04151  PI3K-Akt signaling pathway
            hsa04810  Regulation of actin cytoskeleton
KO_PATHWAY  ko05231
///
